Pfizer has axed its oral GLP-1 asset danuglipron after one patient had potential drug-induced liver injury in a phase 1 trial ...

Growth Drivers include demand for protein-based drugs, rise in chronic disease prevalence, precision medicine expansion, biotech advancements, and AI-driven design tools.Dublin, April 14, 2025 (GLOBE ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy.

Puma Biotechnology offers runway stability but lacks clear growth drivers amid drug headwinds and pipeline gaps. Find out why ...

AZD0780 demonstrated a statistically significant low-density lipoprotein cholesterol reduction when administered on top of ...

AstraZeneca's AZD0780 has demonstrated significant efficacy in a Phase IIb trial, showing a 50.7% reduction in LDL-C after 12 weeks when added to standard statin therapy. The treatment helped 84% ...

Verve Therapeutics has generated evidence its PCSK9 pivot could pay off. | Verve Therapeutics has generated evidence its ...

AstraZeneca (AZ) and Daiichi Sankyo’s Datroway (datopotamab deruxtecan) has been approved by the European Commission (EC) for ...

Eneboparatide hits primary endpoint in AstraZeneca’s Phase 3 trial for chronic hypoparathyroidism, showing significant efficacy at 24 weeks. The EU approved AstraZeneca’s Imfinzi for limited ...

A "huge breakthrough" in breast cancer treatment has arrived with the NHS approval of a twice-daily pill for the most common ...

Treatment consisted of 4-6 cycles of dose-dense intensive chemotherapy incorporating hyperfractionated ...

AstraZeneca to showcase innovation in infectious disease protection at ESCMID Global 2025: Cambridge, UK Thursday, April 10, 2025, 15:00 Hrs [IST] AstraZeneca will share new data ...